Detalhe da pesquisa
1.
REVEAL-1, a phase 2 dose regimen optimization study of vosaroxin in older poor-risk patients with previously untreated acute myeloid leukaemia.
Br J Haematol
; 168(6): 796-805, 2015 Mar.
Artigo
Inglês
| MEDLINE | ID: mdl-25403830
2.
An innovative phase I clinical study demonstrates inhibition of FLT3 phosphorylation by SU11248 in acute myeloid leukemia patients.
Clin Cancer Res
; 9(15): 5465-76, 2003 Nov 15.
Artigo
Inglês
| MEDLINE | ID: mdl-14654525
3.
Bilateral flexor tendon contracture following onychectomy in 2 cats.
Can Vet J
; 46(3): 244-6, 2005 Mar.
Artigo
Inglês
| MEDLINE | ID: mdl-15884646
4.
Hypereosinophilic syndrome: long-term remission following allogeneic stem cell transplant in spite of transient eosinophilia post-transplant.
Am J Hematol
; 78(1): 33-6, 2005 Jan.
Artigo
Inglês
| MEDLINE | ID: mdl-15609294
5.
Phase II study of SU5416--a small-molecule, vascular endothelial growth factor tyrosine-kinase receptor inhibitor--in patients with refractory myeloproliferative diseases.
Cancer
; 97(8): 1920-8, 2003 Apr 15.
Artigo
Inglês
| MEDLINE | ID: mdl-12673719
6.
SU5416, a small molecule tyrosine kinase receptor inhibitor, has biologic activity in patients with refractory acute myeloid leukemia or myelodysplastic syndromes.
Blood
; 102(3): 795-801, 2003 Aug 01.
Artigo
Inglês
| MEDLINE | ID: mdl-12649163